A Phase I Trial of Intracavitary Doxorubicin (Adriamycin) Alternating with Cisplatin

  • Karen Antman
  • Robert Osteen
  • Diane Montella
Part of the Developments in Oncology book series (DION, volume 26)

Abstract

A substantial pharmacologic advantage might be gained by delivering chemotherapy directly into the peritoneum or pleura for tumors confined to these serous cavities. Peak drug levels in ascites after intraperitoneal administration range from 30 to W times that achieved in plasma after intravenous (IV) dosage. (Table 1) If a drug has a high level of hepatic extraction, the plasma concentration after intracavitary (IC) administration of a given dose may be substantially lower than that after IV administration.

Keywords

Toxicity Catheter Creatinine Dehydration Methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE: Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res (42): 4265–4269, 1982.PubMedGoogle Scholar
  2. 2.
    Ozols RF, Willson JKV, Grotzinger KR, Young RC: Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings. Cancer Res (HO): 2743–2747, 1980.PubMedGoogle Scholar
  3. 3.
    Ozols RF, Willson JKV, Weltz MD, Grotzinger KR, Myers CE, Young RC: Inhibition of human ovarian cancer colony formation by Adriamycin and its major metabolites. Cancer Res (40): 4109–4112, 1980.PubMedGoogle Scholar
  4. 4.
    Speyer JL, Collins JM, Dedric RL, Brennan MF, Londer H, DeVita VT, Myers CE: Phase I and pharmacological studies of 5–Fluorouracil administered intraperitoneally. Cancer Res (40): 567–572, 1980.PubMedGoogle Scholar
  5. 5.
    Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High-volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol (1): 1161–1166, 1978.CrossRefGoogle Scholar
  6. 6.
    Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Ballow JW, Brennan MF, Dedrick RJ, DeVita VT: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res (41): 55–59, 1981.PubMedGoogle Scholar
  7. 7.
    Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M: c. Ann Intern Med (97): 845–851, 1982.PubMedGoogle Scholar
  8. 8.
    Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr: Pharmacokinetic study of intraperitoneal (IP) Cisplatin (CP) in patients with malignant ascites. Proc ASCO (1): 22 (C–87), 1982.Google Scholar
  9. 9.
    Paladine WP, Cunningham TJ, Sponzo R. Donovan M, Olson K, Horton J: Intracavitary bleomycin in the management of malignant effusions. Cancer (38): 1903–1908, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Dedrick RL, Myers CL, Bungay PM, DeVita VT Jr: Pharmokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (62): 1–11, 1978.PubMedGoogle Scholar
  11. 11.
    Ozols RF, Looker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (39): 3209–3214, 1979.PubMedGoogle Scholar
  12. 12.
    Roboz J, Chahinian AP, Tosk J, Holland JF: Transport of doxorubicin from peritoneal fluid to plasma in malignant mesothelioma. Proc AACR (22): 229 (#906), 1981.Google Scholar
  13. 13.
    Kefford Rf, Woods RL, Fox RM, Tattersall MHN: Intracavitary Adriamycin, nitrogen mustard and tetracycline in the control of malignant effusions. Med J Australia (2): 447–448, 1980.PubMedGoogle Scholar
  14. 14.
    Tattersall MHN, Fox RM, Newlands ES, Woods RL: Intracavitary doxorubicin in malignant effusions. Lancet (i): 390, 1979.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Karen Antman
  • Robert Osteen
  • Diane Montella

There are no affiliations available

Personalised recommendations